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Background  An association between coffee consumption and cancer has long been 25 
investigated. Coffee consumption among Norwegian women is high, thus this is a favorable 26 
population in which to study the impact of coffee on cancer incidence.   27 
Methods  Information on coffee consumption was collected from 91 767 women at baseline 28 
in the Norwegian Women and Cancer Study. These information were applied until follow-up 29 
information on coffee consumption, collected 6-8 years after baseline, became available.  30 
Multiple imputation was performed as a method for dealing with missing data in the cohort. 31 
Multivariable Cox regression models were used to calculate hazard ratios (HR) for breast, 32 
colorectal, lung, and ovarian cancer, as well as cancer at any site.  33 
Results We observed a 17% reduced risk of colorectal cancer (95%CI 0.70-0.98, ptrend=0.10) 34 
and a 9% reduced risk of cancer at any site (95%CI 0.86-0.97, ptrend=0.03) in women who 35 
drank more than 3 and up to 7 cups/day, compared to women who drank ≤1 cups/day. A 36 
significantly increased risk of lung cancer was observed with a coffee consumption of >7 37 
cups/day (HR=2.01, 95%CI 1.47-2.75, ptrend<0.001). This was most likely caused by residual 38 
confounding due to smoking, as no statistically significant association was observed in never 39 
smokers (>5 cups/day HR=1.42, 95%CI 0.44-4.57, ptrend=0.30). No significant association was 40 
found between coffee consumption and the risk of breast or ovarian cancer.  41 
Conclusions In this study, coffee consumption was associated with a modest reduced risk of 42 
cancer at any site. Residual confounding due to smoking may have contributed to the 43 
positive association between high coffee consumption and the risk of lung cancer. 44 
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The Nordic countries lead the world in coffee consumption. Norway ranks second among 49 
them, with an average consumption of 9.4 kg/year per capita between 1997 and 2011, just 50 
behind Finland (11.7 kg), and ahead of Denmark (8.9 kg) and Sweden (8.1 kg) (1). Therefore, 51 
any causal association between coffee consumption and chronic diseases would have a 52 
significant public health impact in these countries.  53 
We aimed to investigate the relationship between coffee consumption and the risk of 54 
breast, colorectal, ovarian, and lung cancers, as well as cancer at any site, in the Norwegian 55 
Women and Cancer (NOWAC) Study using baseline and follow-up information on total coffee 56 
consumption.  57 
Results from the most recent meta-analysis suggest that high coffee consumption might 58 
be associated with a lower risk of colorectal cancer, and breast cancer in postmenopausal 59 
women (2;3). Moreover, a 27% increased risk of lung cancer was found for the highest coffee 60 
consumption group in a meta-analysis that combined the results of 13 studies, with a 61 
borderline non-significant inverse association being observed among never smokers (4).  No 62 
significant relationship has been reported between coffee consumption and ovarian cancer 63 
(5). Overall, it seems that coffee might have a protective effect against cancer, as reported in 64 
a meta-analysis of 40 prospective cohort studies by Yu et al (6). In Norway, Stensvold and 65 
Jacobsen found a non-significant inverse association between coffee consumption and colon 66 
and rectal cancers in women, and a non-significant, increased risk of breast and lung cancers 67 
(7). 68 
Breast, colorectal, and lung cancer are three of the most frequently diagnosed cancers in 69 
both Norway and worldwide (8;9). Ovarian cancer was included in order to complement the 70 
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study by Gavrilyuk et al (10) on coffee consumption and the risk of gynecologic tumors in the 71 
NOWAC Study. 72 
Methods 73 
The NOWAC study 74 
Detailed information on the NOWAC Study is available elsewhere (11). In short, random 75 
samples of Norwegian women aged 30-70 years were invited to participate. More than 172 76 
000 accepted and completed a questionnaire regarding their lifestyle, diet, and health status 77 
(overall response rate: 52.7%). All women gave written informed consent. The NOWAC Study 78 
was approved by the Regional Committee for Medical Research Ethics and the Norwegian 79 
Data Inspectorate. 80 
The cohort follow-up was conducted between 1996 and 2013. The baseline information 81 
in this analysis were taken from the questionnaires of women enrolled in 1991-1992, 1996-82 
1997, 2003, and 2004. These women completed baseline food frequency questionnaires in 83 
1998, 1996-1997, 2003, and 2004, respectively. We chose not to use the information 84 
collected during the first wave of data collection (1991-1992) as the version of 85 
questionnaires that was sent out did not include questions regarding diet. We decided to use 86 
the information from the questionnaires sent in 1998 (the second wave of data collection) 87 
for those women enrolled in the NOWAC from 1991-1992 as baseline data for the present 88 
study. The information on coffee consumption was available for 98 405 women.   89 
We excluded women with prevalent cancer other than non-melanoma skin cancer at 90 
baseline and those who emigrated or died before the start of follow-up (N=4395), those who 91 
were diagnosed with cancer after they emigrated (N=9), and those with total energy intake 92 
above 15 000 kJ or below 2500 kJ per day (N=619). Finally, we excluded 1615 women that 93 
had missing information on coffee consumption at baseline, i.e. the women who did not 94 
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answer to none of the three questions regarding boiled, instant and filtered coffee intake in 95 
the first questionnaire.  Thus, the final analytical study sample consisted of 91 767 women. 96 
Follow-up information were collected from 79 461 of these women, who received the 97 
follow-up questionnaire before the end of the study, 6-8 years after baseline data collection. 98 
The rest of the women (N=12 306) received the baseline questionnaire in 2004, while the 99 
follow-up questionnaire was sent out to them after the present study has ended. 100 
Assessment of coffee consumption and covariates 101 
Women answered the same question on coffee consumption at baseline and at follow-up: 102 
“How many cups of each kind of coffee (boiled, filtered, instant) did you usually drink during 103 
the past year?” Women could choose from the following answers: never/seldom, 1-6 104 
cups/week, 1 cup/day, 2-3 cups/day, 4-5 cups/day, 6-7 cups/day, and ≥8 cups/day for each 105 
brewing method. Total coffee consumption was derived by summing the frequencies of each 106 
of the brewing methods and was categorized as ≤1 cup/day (light consumers), more than 1 107 
up to 3 cups/day (low moderate consumers), more than 3 up to 7 cups/day (high moderate 108 
consumers), and >7 cups/day (heavy consumers). As the size of a cup was not specified in 109 
the questionnaire, 2.1 dl was used as the standard cup size (12). 110 
Women also answered questions on smoking status (never, former, or current), and 111 
number of pack-years (calculated as number of cigarettes smoked/day divided by 20 and 112 
multiplied by years of smoking) at baseline and at follow-up.  Women who reported they 113 
were current or former smokers at baseline and never smokers at follow-up were 114 
categorized as former smokers at follow-up (N=1608). Additionally, the information on BMI, 115 
physical activity, alcohol consumption, total energy intake, and use of hormone replacement 116 




Cancer incidence, death, and emigration 119 
Information on cancer incidence, death, and emigration in the cohort was obtained through 120 
linkage to the Norwegian Cancer Registry, the Cause of Death Registry, and the Norwegian 121 
Central Population Register, respectively, using the unique 11-digit personal number 122 
assigned to every legal resident in Norway. The 7th Revision of the International Statistical 123 
Classification of Diseases, Injuries and Causes of Death was used to classify breast (170.0-124 
170.9), colorectal (153.0-154.0), ovarian (175.0-175.9), and lung (162.0-162.1) cancer cases 125 
in the Cancer Registry of Norway.  126 
Statistical methods 127 
As per the methods proposed by Hu et al (13), we applied baseline information until follow-128 
up information became available, until date of diagnosis of any incident cancer other than 129 
non-melanoma skin cancer, death, or emigration, whichever occurred first. Thereafter 130 
follow-up information was applied until diagnosis of any incident cancer other than non-131 
melanoma skin cancer, until death, emigration or the end of the study period (31 December 132 
2013), whichever occurred first. 133 
Cox proportional hazards regression models were used to calculate hazard ratios (HRs) 134 
for developing breast, colorectal, ovarian, or lung cancer, as well as cancer at any site other 135 
than non-melanoma skin cancer, with 95% confidence intervals (CIs) for each coffee 136 
consumption group. Light consumers (i.e., those drinking ≤1 cup/day), were used as the 137 
reference group, as it was impossible to differentiate between coffee abstainers and 138 
occasional coffee drinkers from the answers offered in the questionnaire. Attained age was 139 
used as the underlying time scale. All models were stratified by questionnaire subcohorts in 140 
order to control for potential differences in the long follow-up time. 141 
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We decided to use follow-up information on smoking exposure in addition to coffee 142 
consumption, for both complete-case analyses and analyses performed on multiple imputed 143 
datasets. This was done as the prevalence of current smokers varied over time in the cohort, 144 
and as we suspected a strong confounding effect of the smoking exposure in the analyses. 145 
Analyses for each cancer site were adjusted for known risk factors (9) in the preliminary, 146 
complete-case analysis, which included baseline information only. The preliminary models 147 
for each cancer site were adjusted for a selection of the following covariates: menopausal 148 
status (premenopausal/postmenopausal), smoking status (never, former, current), age at 149 
smoking initiation (<20, ≥20 years), number of pack-years (≤14, 15-19, ≥20), exposure to 150 
cigarette smoke during childhood (yes/no),  duration of education (≤9, 10-12,  13-16,  ≥17 151 
years), body mass index (BMI, ≤18.49, 18.5-24.9, 25-29.9, and ≥30 kg/m2), physical activity 152 
level (1-4, 5-6, 7-10), alcohol consumption (0, 0.1-3.99, 4-9.99, ≥10 g/day), number of 153 
children (0, 1-2, ≥3), age at first birth (<20, 20-24, 25-29, ≥30 years), ever use of oral 154 
contraceptives (yes/no), duration of oral contraceptive use in years (continuous), use of 155 
hormone replacement therapy (never, former, current), maternal history of breast cancer 156 
(yes/no), total energy intake (tertiles, kJ/day), intake of fibers (<=20, >20 g/day), intake of 157 
processed meat (continuous, g/day), intake of red meat (<=10, 10.01-20, >20, g/day), height 158 
(continuous, cm), and participation in mammography screening (yes/no). In order to be 159 
retained in the final model, the removal of the covariate had to lead to a change in the 160 
regression coefficients of at least 10% in any of the coffee consumption groups.  161 
If a linear trend was observed for a specific covariate, that covariate was treated as 162 
continuous. When the adjustment required all the smoking variables in the analysis, we 163 
modelled these as five categorical variables, which included the information on smoking 164 
status, age at smoking initiation, and number of pack-years. Similarly, 12 categorical 165 
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variables were made by combining the information on number of children and age at first 166 
birth for the breast cancer analysis. As in other large cohort studies, when age at menopause 167 
was not available, the age 53 years was used as the threshold by which to classify 168 
premenopausal and postmenopausal women in the complete-case analyses (14).   169 
An interaction between coffee consumption and the logarithmic transformation of 170 
participants’ age was tested to check the proportional hazards assumption. To test for linear 171 
trend, a median value was assigned to each category of ordinal coffee consumption variable, 172 
which was then modeled as continuous in the analyses. We assessed possible interactions 173 
between coffee consumption and smoking status, BMI, and physical activity level, 174 
respectively, as these had the potential to interact with the antioxidant effects of coffee, or 175 
could affect the metabolism of coffee compounds (15-17). 176 
In order to counteract residual confounding due to smoking, we repeated the analysis on 177 
lung cancer using women that were never smokers during the entire study period.  For this 178 
analysis, we classified heavy consumers as those drinking >5 cups/day in order to increase 179 
number of cases in the highest coffee consumption category. We have also conducted 180 
complete-case sensitivity analyses in which we have used, depending on the outcome, the 181 
follow-up information on BMI, physical activity, alcohol consumption, total energy intake, or 182 
use of hormone replacement therapy. As a complementary analyses, we conducted an 183 
analysis for colon and rectal cancers separately. We repeated the analyses for each of the 184 
outcomes after excluding cancers at the corresponding sites diagnosed during the first two 185 
years of follow-up in order to control for possible reverse causality. Furthermore, we did the 186 
analyses in which we had excluded cancer cases of interest that occurred during the first 187 
year of follow-up, and at the same time censoring at the time of answering the second 188 
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questionnaire those cancer cases diagnosed during the first year after they received the 189 
second questionnaire. 190 
Multiple imputation 191 
Under the assumption that data was missing at random, and after confirming that the 192 
pattern of missingness was arbitrary, we performed multiple imputation to deal with missing 193 
information at baseline and follow-up. Twenty duplicate datasets were created in order to 194 
reduce sampling variability from the imputation simulation (18). The missing values from 195 
baseline and follow-up were then replaced by imputed values based on the observed 196 
information. Separate imputation models were created for each outcome, including all of 197 
the variables from the final analysis of the specific cancer sites. In addition, in order to 198 
increase the predictive power of the imputation procedure, we included smoking status and 199 
number of pack-years (baseline and follow-up information), and age at smoking initiation, 200 
duration of education, BMI, physical activity level, and alcohol consumption (baseline 201 
information) in each imputation model, regardless of whether the variable(s) were used in 202 
the multivariable Cox regression model. 203 
In order to avoid possible inconsistencies, we imputed the “change in smoking status” 204 
between baseline and follow-up. Later, we used these imputed values to determine if a 205 
person was a never, former, or current smoker at follow-up. Similarly, we imputed the 206 
difference in the number of pack-years between baseline and follow-up, in order to avoid 207 
lower imputed values at follow-up compared to baseline.     208 
 If the interaction term between coffee consumption and any one of the variables 209 
smoking status, BMI, or physical activity level was statistically significant in the complete-210 
case analysis, these terms were included as predictors in the imputation model. We also 211 
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used the Nelson-Aalen cumulative hazard estimator as a predictor in all the imputation 212 
models (19).  213 
The estimates from the twenty imputed datasets were combined using Rubin’s rules in 214 
order to obtain HRs and corresponding 95% CIs (20). All the analyses and the multiple 215 
imputations were done in STATA version 14.0 (Stata Corp, College Station, TX, USA). 216 
 217 
Results 218 
During an average of 13.1 years of follow-up and 1.2 million person-years, 9675 cases of 219 
cancer were diagnosed: 3277 (33.9%) breast cancers, 1266 (13.1%) colorectal cancers, 446 220 
(4.6%) ovarian cancers, and 819 (8.5%) lung cancers. The ten most common cancer sites in 221 
the NOWAC study are presented in Supplementary table 1. At baseline, most women 222 
reported they were high moderate consumers (more than 3 up to 7 cups/day; 42.8%). At 223 
follow-up, the proportion of high moderate consumers and heavy consumers (>7 cups/day) 224 
decreased. Distribution of participants according to filtered, instant, and boiled coffee 225 
consumption at baseline and follow-up is presented in Supplementary table 2.  226 
The proportion of women diagnosed with cancer at any site was largest among heavy 227 
consumers (12.4%); this was also the case for lung cancer (2.4%). Light consumers (≤1 228 
cup/day) were more likely to have fewer children, were the oldest at the time of first birth, 229 
were more likely to have used oral contraceptives, and had the lowest energy intake 230 
compared to women in other coffee consumption groups. Heavy consumers were the 231 
youngest at baseline, had the highest BMI, and the lowest physical activity level score. In 232 
addition, these women consumed less alcohol, had more children, were younger at first 233 
birth, and were less likely to have used hormone replacement therapy compared to women 234 
in other coffee consumption groups (Table 1). 235 
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The proportion of current smokers was the lowest among light coffee consumers, and 236 
became higher in each subsequent coffee consumption category, with the percentage 237 
among heavy consumers reaching 68.5%. A positive relationship was also observed between 238 
both number of pack-years and age at smoking initiation, and the number of cups/day of 239 
coffee consumed. In contrast, we found a negative trend for coffee consumption and 240 
duration of education, with light consumers averaging 13 years of school, compared to the 241 
10.6 years observed among heavy consumers (Table 1).   242 
The highest proportion of missing values was observed for age at menopause at baseline 243 
and follow-up (54.4%), coffee consumption at follow-up (27.0 %), smoking status at follow-244 
up (27.4 %), and number of pack-years at follow-up (42.8 %). The highest proportion of 245 
missing information on coffee consumption at follow-up was observed among those who 246 
reported being light consumers at baseline. Women that were heavy coffee consumers were 247 
more likely to have missing information on smoking at both baseline and follow-up (Table 2).  248 
The comparison between the complete-case dataset and the dataset with imputed values 249 
are presented in Supplementary Table 3. The results of the complete-case analysis for each 250 
of the outcomes are reported in Supplementary Table 4. 251 
The following results are those from the analyses performed on the imputed datasets. 252 
We observed a 9% reduction in the risk of cancer at any site among high moderate 253 
consumers compared to light coffee consumers (HR=0.91, 95% CI 0.86-0.97, ptrend=0.03) 254 
(Table 3). There was no significant association between coffee consumption and the risk of 255 
breast cancer when heavy consumers were compared with the reference group (HR=0.87, 256 
95% CI 0.71-1.06, ptrend=0.06). A borderline non-significant HR of 0.91 was found among high 257 
moderate consumers (95% CI 0.82-1.00). A statistically significant inverse association 258 
between coffee consumption and the risk of colorectal cancer was found only in high 259 
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moderate consumers, with no significant linear trend (HR=0.83, 95% CI 0.70-0.98, 260 
ptrend=0.10). No association was found between coffee consumption and the risk of ovarian 261 
cancer (highest vs. lowest consumption category HR=0.87, 95%CI 0.50-1.51, ptrend=0.89). 262 
Compared to light consumers, heavy consumers had a more than five-fold higher risk of lung 263 
cancer in the age-adjusted analysis. (95% CI 4.20-7.60). This association was attenuated after 264 
multivariable adjustment, but an increase in risk was still observed in the highest coffee 265 
consumption group (HR=2.01, 95% CI 1.47-2.75, ptrend<0.001) (Table 3). 266 
We found no statistically significant association between coffee consumption and the 267 
risk of lung cancer among never smokers (HR=1.42 among women who drank >5 cups/day, 268 
95% CI 0.44-4.57, ptrend=0.30) (Table 4). 269 
None of the interactions tested between coffee consumption and smoking status, BMI, 270 
and physical activity level were significant in any of the outcomes investigated (data not 271 
shown). We found no interaction effect between coffee consumption and the logarithmic 272 
transformation of age in any of the outcomes. 273 
The risk estimates for, colorectal, ovarian, lung and cancer at any site from the lag 274 
analyses were similar to those from the analyses that included the entire study sample 275 
(results not shown). However, we observed a significantly decreased risk of breast cancer for 276 
low and high moderate coffee consumers after we excluded breast cancer cases diagnosed 277 
during the first two years of follow-up (HR=0.90, 95% CI 0.81-0.99; HR=0.86, 95% CI 0.78-278 
0.96, ptrend=0.01). 279 
The complete-case analyses in which follow-up information on BMI, physical activity, 280 
alcohol consumption, total energy intake and use of hormonal replacement therapy were 281 
used in addition to coffee and smoking exposure variables, revealed similar results with the 282 
analyses in which only coffee and smoking variables were updated (results not shown). 283 
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Finally, in both complete-case and the analyses on multiple imputed datasets performed for 284 
colon and rectal cancers separately, we found no evidence of an association between coffee 285 
consumption and either colon or rectal cancer risk (Supplementary table 5). 286 
The associations between coffee consumption and the risk of breast, colorectal, lung, 287 
and ovarian cancer, as well as cancer at any site among never smokers are presented in 288 
Supplementary table 6. 289 
 290 
Discussion 291 
We observed a decreased risk of colorectal cancer and of cancer at any site associated with 292 
high moderate coffee consumption, with no evidence of linear relationship between coffee 293 
consumption and colorectal cancer risk. In contrast, we found a statistically significant 294 
association between high coffee consumption (>7 cups/day) and the risk of lung cancer. 295 
However, no significant association between coffee intake and the risk of lung cancer was 296 
observed in never smokers. 297 
The main strengths of our study include its prospective design, the relatively large 298 
sample size, and the statistical power necessary to detect differences between the coffee 299 
consumption groups in each of the studied cancer sites. The participants in the NOWAC 300 
cohort were randomly recruited from the general population. The external validity of 301 
NOWAC study has been previously found to be acceptable. Briefly, the response rate from 302 
the NOWAC study is similar to many other populated-based cohorts. The authors found that 303 
the responders do not differ materially from the source population except for somewhat 304 
higher educational level. Similarly, the observed incidence rates for all cancer sites in the 305 
NOWAC study were comparable to national figures (21). Linkage to the Norwegian Cancer 306 
Registry via the unique person number allowed us to obtain virtually complete follow-up. 307 
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The food frequency questionnaires used in the NOWAC Study were validated by 24-h dietary 308 
recalls study (12), which showed a high validity of information on coffee consumption 309 
(Spearman’s correlation coefficient r=0.82). We used repeated measurements of coffee 310 
consumption and smoking exposure in order to take into account changes in these variables 311 
over time and to attenuate the risk of measurement error. Moreover, the use of the updated 312 
information on coffee consumption allowed us to conduct an extensive lag analysis in order 313 
to check for possible reverse causality. Finally, we used multiple imputation to maximize the 314 
number of participants and cancer cases included the analyses.         315 
There are also several limitations in our study.  We lacked power to explore the risk of 316 
some cancer sites such as liver that were found to be inversely associated with coffee intake. 317 
The risk of hepatocellular carcinoma was previously reported to be lower in the higher 318 
categories of coffee consumption (22;23). During the follow-up, 44 women were diagnosed 319 
with primary liver and biliary passages cancer in the present study. Any analysis with this low 320 
number of cases would lead to unreliable results. We did not have information regarding 321 
caffeination status. However, the consumption of decaffeinated coffee is very uncommon in 322 
Norway. We did not conduct a separate analysis for different brewing types of coffee, as the 323 
number of women that reported drinking more than 7 cups of instant or boiled coffee at 324 
baseline was low (213 and 999, respectively). As the consumption of boiled coffee is 325 
decreasing in the cohort, the number of participants in the highest coffee consumption 326 
category was not sufficient for analyses of either of these brewing types. We believe, 327 
however, that our results were driven by filtered coffee, which was the most commonly 328 
consumed among women in the cohort.   329 
The effect of residual confounding cannot be excluded, although we adjusted for many 330 
known risk factors. This may particularly be the case for the association between heavy 331 
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coffee consumption and the risk of lung cancer, which is most likely due to residual 332 
confounding from smoking. Indeed, there were pronounced differences in coffee 333 
consumption between never, former, and current smokers in the cohort.  As the proportion 334 
of daily smokers in Norway is decreasing (24), adjusting for only baseline information on 335 
smoking exposure could have yielded biased estimates. However, we lacked the information 336 
necessary to adjust for more comprehensive markers of smoking exposure, such as if a 337 
person inhales smoke from a cigarette, or lifetime exposure to secondhand smoke and other 338 
pollutants. Tea consumption was not taken into account in the analyses, as this information 339 
was not available from the NOWAC questionnaires. Therefore, a possible confounding effect 340 
of tea, which contains some of the same bioactive components as coffee, cannot be 341 
excluded.  342 
Although the information on coffee consumption was shown to be valid based on the 343 
results from the validation study, misclassification is still possible. We tried to reduce within-344 
person variation and minimize the risk of misclassification bias by using follow-up 345 
information. However, as coffee consumption was self-reported, misclassification cannot be 346 
completely ruled out. 347 
We decided to impute missing information at baseline and follow-up, assuming a 348 
missing-at-random mechanism. We introduced a wide range of variables into the imputation 349 
models, which we thought could be used to predict incomplete variables or to predict 350 
whether the incomplete variable was missing (25). However, it is possible that at least some 351 




To our knowledge, this is the first study examining the effect of coffee consumption on 354 
the risk of cancer that used repeated information on coffee consumption and combined this 355 
method with multiple imputation of missing data. 356 
The results from our study are in line with the meta-analysis by Yu et al regarding coffee 357 
intake and the overall risk of cancer, in which a 13% risk reduction was found in women. 358 
However, the study authors did not specify which coffee consumption group was compared 359 
to the non/lowest drinking category (6). In a prospective study from Norway, which included 360 
21 238 women, a non-significant inverse association was observed in the highest coffee 361 
consumption group (≥7 cups/day) (7). The results from the Swedish Västerbotten 362 
Intervention Project (VIP) cohort showed a non-significant HR of 0.92 for all cancer sites in 363 
both men and women who drank coffee on at least 4 occasions per day compared to the 364 
reference group (26).   365 
Our findings regarding the risk of breast cancer are in accordance with the recent meta-366 
analysis, as well as with the studies from Norway, France, Netherlands, and Sweden (3;7;27-367 
29). In addition, the results from Nurses’ Health Study, which included follow-up information 368 
on coffee consumption support our findings (≥4 cups/day HR=0.92 95% CI 0.82-1.03) (30).  369 
No significant associations were also found between total coffee consumption and the risk 370 
of breast cancer in pre- or postmenopausal women in the EPIC study (31). On the other 371 
hand, another study from Sweden found a significant 19% decrease in risk among women 372 
who drank at least 5 cups of coffee per day (32). We did, however, find a similar risk 373 
reduction for the women drinking more than 3 and up to 5 cups of coffee/day, after we 374 
excluded breast cancer cases that were diagnosed during the first two years after enrollment 375 
in the study. 376 
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Our results regarding the risk of colorectal cancer depart somewhat from the findings of 377 
other cohort studies. Studies from Sweden and the United States also utilized updated 378 
information on coffee consumption, but found no association between high coffee 379 
consumption and the risk of colorectal cancer in women (33;34). Authors from the EPIC 380 
cohort also concluded that coffee consumption was not likely to be associated with the risk 381 
of colorectal cancer, as did the authors of the Japan Collaborative Cohort Study for the 382 
Evaluation of Cancer Risk (35;36). In the most recent meta-analysis, a significant inverse 383 
association was found in women after pooling the results from 25 case-control studies 384 
(summary OR=0.82). However, no such findings were found in the meta-analysis that 385 
included cohort studies (2). However, even though we found an association between high 386 
moderate coffee consumption and colorectal cancer risk, an absence of a linear relationship 387 
supports the findings from the mentioned studies. Furthermore, coffee consumption was 388 
associated with neither colon nor rectal cancer in the separate analyses. 389 
The observed differences in the results regarding the risk of colorectal cancer might be 390 
due to differences in the potential confounders that were taken into account in the analyses. 391 
Indeed, the only study that carried out a detailed adjustment for smoking exposure that was 392 
comparable to ours was the EPIC study. Lack of adjustment for family history of colorectal 393 
cancer, the information not available for our cohort, could partially explain the differences 394 
between our study results and those from Japan, Sweden, and the United States. 395 
Our findings regarding ovarian cancer are in agreement to those from the European 396 
Prospective Investigation into Cancer and Nutrition (EPIC) cohort, and from a meta-analysis 397 
by the same authors, both of which showed no association between high coffee 398 
consumption and the risk of ovarian cancer (5). 399 
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In an updated meta-analysis of epidemiological studies, Xie et al found a significant 400 
positive association between high coffee consumption and lung cancer in men, while a non-401 
significant summary OR of 1.16 was observed for women in the highest coffee consumption 402 
category (37). One possible explanation for the difference between the meta-analysis and 403 
the present study was that Xie et al used 3 cups/day as the cut-off between the moderate 404 
and highest coffee consumption group. Similarly, in a recent study from the United States, a 405 
non-significant higher risk of lung cancer in women was associated with the highest level of 406 
coffee intake, defined as ≥4 cups/day (HR=1.10; 95% CI 0.95-1.26) (38). Finally, a study from 407 
Norway found a two-fold increased risk of lung cancer in women that were consuming at 408 
least 7 cups of coffee per day (7). Residual confounding by smoking is likely to have  409 
influenced the effect estimates in our study, as well as in previous studies. A strong 410 
correlation between smoking habits and coffee consumption can be at least partially 411 
explained by the fact that caffeine and nicotine share a metabolic pathway, via the CYP1A2 412 
gene (39;40). It seems that an analysis with a sub-optimal adjustment for smoking exposure 413 
would likely yield a positive association between coffee consumption and the risk of lung 414 
cancer. This is also supported by the lack of statistically significant association we observed 415 
between coffee consumption and risk of lung cancer among never smokers, as was also 416 
found in the study by Guertin et al (38). Our results among never smokers are in line with 417 
two meta-analyses in which no significant associations were observed between coffee intake 418 
and the risk of lung cancer (4;37). However, an inverse association reported in the meta-419 
analyses contradict the positive association in the present study. Our analysis was, however, 420 
hampered by a small number of lung cancer cases among never smokers. As the result, the 421 
interpretation of these results warrants some caution. 422 
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A number of biologically active substances contained in roasted coffee have the potential 423 
to either suppress or induce carcinogenesis. Chlorogenic acid is one of the ingredients that 424 
contributes significantly to the antioxidant effect of coffee. It has been hypothesized that 425 
chlorogenic acid could alter the risk of some cancers by reducing glucose levels in the blood 426 
and increasing insulin sensitivity (41;42). Kahweol, one of the diterpenes that constitutes 427 
coffee, has been found to induce apoptosis in human leukemia cells (43), to reduce 428 
gentoxicity in hepatoma cells (44), and to induce synthesis of endogenous antioxidants (45). 429 
Caffeine has also been shown to alter the risk of malignancies in pre- and postmenopausal 430 
women by increasing the level of sex-hormone binding globulin and decreasing the levels of 431 
free estradiol (46).  432 
Even though the observed positive association between coffee consumption and the risk 433 
of lung cancer is likely due to residual confounding from smoking, we cannot rule out the 434 
possibility of a biological effect of some coffee compounds on lung cancer.  The adverse 435 
effects of caffeine are mainly related to its ability to inhibit DNA repair mechanisms (47;48). 436 
Muller et al argued that caffeine negatively effects both the speed of DNA repair, and the 437 
residual damage after exposing mammalian cells to radiation (49).  438 
 439 
Conclusion 440 
The results from our study indicate that high moderate coffee intake may have a protective 441 
effect on the overall risk of cancer. The observed positive association between heavy coffee 442 
consumption and the risk of lung cancer should be interpreted with caution, as residual 443 
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